Lamivudina Farmoz (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics natural nucleosides. When HIV reverse transcriptase incorporates lamivudine triphosphate into viral DNA, it terminates the DNA chain, halting further replication of the virus and limiting infection spread.

The specific dose of Lamivudina Farmoz is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function, and other clinical factors. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety of lamivudine during pregnancy or lactation should be evaluated by a qualified healthcare provider. The prescriber will weigh potential benefits against any possible risks to the mother and child before deciding whether the medication is appropriate in these situations.

To request Lamivudina Farmoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient oral administration. Compared with some protease inhibitors, it has fewer metabolic side effects, but it is typically used in combination with other antiretrovirals to achieve optimal viral suppression and reduce resistance risk.

Lamivudina Farmoz should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency throughout its shelf life.

Lamivudina Farmoz is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include lactic acidosis, severe hepatomegaly with steatosis, hypersensitivity reactions, and pancreatitis. Patients should promptly report symptoms such as unexplained fatigue, abdominal pain, rapid breathing, or skin rash to their healthcare provider for immediate evaluation.

Lamivudina Farmoz is contraindicated in individuals with known hypersensitivity to lamivudine or any of its excipients. Patients with severe renal impairment may require dose adjustment, and those with active liver disease should be closely monitored. The prescriber will assess suitability on a case‑by‑case basis.